Results 91 to 100 of about 5,094 (245)
Psychedelics Promote Structural and Functional Neural Plasticity. [PDF]
, 2018 Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast ...
Barragan, Eden V +15 more
core +2 more sources
Addiction, EarlyView.Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Trends in fentanyl‐containing drug samples seized by law enforcement agencies across Canada
Addiction, EarlyView.Abstract Background and aims Canada's drug toxicity crisis has been largely attributed to a volatile fentanyl‐dominated unregulated drug supply with increasing reports of fentanyl detected in combination with benzodiazepines, stimulants and xylazine.
Shaleesa Ledlie +6 more
wiley +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Swiss Medical Weekly, 2015 Novel psychoactive substances are newly used designer drugs (“internet drugs”, “research chemicals”, “legal highs”) potentially posing similar health risks to classic illicit substances.
Matthias Liechti
doaj +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives [PDF]
Many N,N-dialkylated tryptamines show psychoactive properties in humans and the number of derivatives involved in multidisciplinary areas of research has grown over the last few decades.
Brandt, SD +7 more
core +1 more source
Correlation between blood and oral fluid psychoactive drug concentrations and cognitive impairment in driving under the influence of drugs [PDF]
, 2017 The effects of drugs on driving performance should be checked with drug concentration in the brain and at the same time with the evaluation of both the behavioural and neurophysiological effects. The best accessible indicator of this information is the
Busardò, Francesco Paolo +6 more
core +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Designer drugs: aspectos analíticos e biológicos
Química Nova, 2012 In the recent years, analytical toxicologists have been facing difficulties in detecting designer drugs due to the chemical modifications on the existing structures and the speed in which they are released into the market, requiring the development and ...
Rachel Bulcão +7 more
doaj +1 more source